POLY MEDICURE LIMITED

215.35 -3.98 (-1.85%) Sell

POLYMED investors looking to exit as part of sectoral rotation

13 min read

POLY MEDICURE LIMITED was among the worst performers on Friday. It delivered -1.85% to close at 215.35. On a day when the overall market breadth was 71%, it closed higher than 64% of the market. In comparison, the benchmark NIFTY-50 index closed today at +0.02%.

[Themes containing POLYMED]

Buy-and-Hold investors in POLYMED experienced a maximum drawdown of -12.25% over the last three months. It delivered -2.31% during this bearish trending period. There were both Long and Short signals during this period, where the short signals were marginally more profitable than the long signals.

Trend

POLYMED has been underperforming the NIFTY-50 index in recent time. It showed significant underperformance (compared to the NIFTY-50 index) from 20 Mar, 2017 to 21 Jun, 2018. Over the last 3 years and 1 month, POLYMED underperformed the NIFTY-50 index on 53% days.

During the last three months POLYMED delivered profits on 52% days. However, it still managed to end this period in a loss. It's best return during this period (of +8.51%) was on Monday, 3 Dec, 2018. While it's worst loss in the same period (of -4.26%) was on Tuesday, 20 Nov, 2018. The longest stort-term trend during this period was 7 profitable days, which started on 27 Nov, 2018 and went on till 5 Dec, 2018. This bullish trend returned +15.98% to investors.

The last 12 months saw POLYMED's investors making profits in 6 months and incurring losses in 6 months. During the last year, POLYMED delivered profits in more months than NIFTY-50 index. POLYMED significantly outperformed NIFTY-50 index in Jul 2018, when it returned +13.33% compared to +6.56% returned by NIFTY-50 index during it's best month in the last one year - Jul 2018. POLYMED and NIFTY-50 index, both had periods of 2 consecutive profitable months. It is interesting to note that both POLYMED and NIFTY-50 index significantly outperform during months when quarterly/annual results are announced.

"The monarchy is foremost a business, and it's important to them that the British public continue to finance the excessive luxurious lifestyles of the now quite enormous, wasteful and useless 'royal' family. I find it very sad.

POLYMED is currently seeing overall fall in volatility. In comparison, the NIFTY-50 index is seeing decrease in volatility. During the last three months, there was a significant fall in POLYMED's volatility from 3 Dec, 2018 to 17 Jan, 2019. While there was a significant fall in the NIFTY-50 index's volatility from 31 Oct, 2018 to 5 Dec, 2018.

Advanced/professional short-term investors should note that POLYMED has significant negative skewness in it's return distribution. This indicates that POLYMED is very risky for short-term investment and can significantly underperform for long durations.

NIFTY-50 index has more chance of extreme outcomes than POLYMED. Therefore, NIFTY-50 must receive a lower allocation than POLYMED in your portfolio. NIFTY-50 index usually has shorter drawdown period than POLYMED.

Based on your interest in POLYMED you may find it interesting to know that VINATIORGA, RESPONIND and ASTRAZEN are small caps that have all shown remarkable performance and qualify to be on every investor's watchlist.

Want to improve your Portfolio's performance?

Spotalpha's Portfolio optimizer is all you need to improve your returns and reduce your risk.
Optimize Portfolio NOW
If you liked what you read here ...

... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.

All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.

We want to empower investors with all the tools and analysis required by them to make a rational investment decision.

If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute
Share with friends   WhatsApp   Facebook   Twitter